Mostrar registro simples

dc.contributor.authorCivallero, Gabriel Eduardo Santiagopt_BR
dc.contributor.authorKubaski, Francynept_BR
dc.contributor.authorPereira, Danilopt_BR
dc.contributor.authorRübensam, Gabrielpt_BR
dc.contributor.authorHerbst, Zackary M.pt_BR
dc.contributor.authorSilva, Camilopt_BR
dc.contributor.authorTrapp, Franciele Barbosapt_BR
dc.contributor.authorPoletto, Édinapt_BR
dc.contributor.authorFaqueti, Larissa Gabrielapt_BR
dc.contributor.authorIop, Gabrielle Dineckpt_BR
dc.contributor.authorSoares, Julianopt_BR
dc.contributor.authorLinden, Vanessa van derpt_BR
dc.contributor.authorLourenço, Charles Marquespt_BR
dc.contributor.authorGiugliani, Robertopt_BR
dc.date.accessioned2022-07-28T04:45:29Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn2214-4269pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/245608pt_BR
dc.description.abstractAromatic l-amino acid decarboxylase (AADC, EC 4.1.1.28) deficiency is a rare genetic disorder characterized by developmental delay, oculogyric crises, autonomic dysfunction and other problems, caused by biallelic mutations in the DDC gene leading to deficient activity of aromatic l-amino acid decarboxylase, an enzyme involved in the formation of important neurotransmitters, such as dopamine and serotonin. A clinical development program of gene therapy for AADC deficiency is ongoing. An important step for the success of this therapy is the early and precise identification of the affected individuals, but it has been estimated that around 90% of the cases remain undiagnosed. The availability measurement of the AADC activity is mandatory for an accurate biochemical diagnosis. Based on these statements, our objectives were to develop a liquid chromatography tandem mass spectrometry (LC-MS/MS) method suitable for the determination of the AADC activity, and to evaluate its capacity to confirm the deficiency of AADC in potential patients in Brazil. The AADC activities were measured in plasma samples of seven AADC deficient patients and 35 healthy controls, after enzymatic reaction and LC-MS/MS analysis of dopamine, the main reaction product. The results obtained showed clear discrimination between confirmed AADC deficient patients and healthy controls. The method presented here could be incorporated in the IEM laboratories for confirmation of the diagnosis of when a suspicion of AADC deficiency is present due to clinical signs and/or abnormal biomarkers, including when an increased level of 3-O-methyldopa (3-OMD) is found in dried blood spots (DBS) samples from high-risk patients or from newborn screening programs.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofMolecular genetics and metabolism reports. New York. Vol. 32 (2022), 100888, 4 p.pt_BR
dc.rightsOpen Accessen
dc.subjectAromatic l-amino acid decarboxylaseen
dc.subjectDiagnósticopt_BR
dc.subjectBioquímicapt_BR
dc.subjectAADC deficiencyen
dc.subjectDDC gene3-ortho-methyl-dopaen
dc.subjectPlasmapt_BR
dc.subjectEspectrometria de massas em Tandempt_BR
dc.subject3-OMDen
dc.subjectDopamineen
dc.subjectCromatografia líquidapt_BR
dc.subjectTandem mass spectrometryen
dc.titleBiochemical diagnosis of aromatic-L-amino acid decarboxylase deficiency (AADCD) by assay of AADC activity in plasma using liquid chromatography/tandem mass spectrometrypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001145715pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples